Transforming growth factor beta 1 and sodium butyrate differentially modulate urokinase plasminogen activator and plasminogen activator inhibitor-1 in human breast normal and cancer cells

British Journal of Cancer

Volumn 77, Issue 3, 1998, Pages 396-403

  Dong Le Bourhis, X ^a   Lambrecht, V ^a   Boilly, B ^a  

^a UNIV LILLE   (France)

Author keywords

Breast epithelial cells; Plasminogen activator inhibitor 1; Sodium butyrate; Transforming growth factor beta 1; Tumour invasion; Urokinase plasminogen activator

Indexed keywords

BUTYRIC ACID; PLASMINOGEN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA1; UROKINASE;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL;

EID: 0031983263     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.63     Document Type: Article

References (34)

1. Achbarou A, Kaiser S, Tremblay G, Ste-Marie LG, Brodt P, Goltzman D and Rabbani SA (1944) Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 54: 2372-2377
2. Andresen PA, Georg B, Lung LR, Riccio A and Stacey SN (1990) Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 68: 1-19
3. Arnoletti JP, Albo D, Granick MS, Solomon MP, Castiglioni A, Rothman VL and Tuszynski GP (1995) Thombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells. Cancer 76: 998-1005
4. Arrick BA, Korc M and Derynck R (1990) Different regulation of expression of three transforming growth factor beta species in human breast cancer cell lines by estradiol. Cancer Res 50: 299-303
5. Berthon P, Pancino G, De Cremoux P, Roseto A, Gespach C and Calvo F (1992) Characterization of normal breast epithelial cells in primary cultures: differentiation and growth factor receptor studies. In Vitro Cell Dev Biol 28: 716-724
6. Blasi F (1993) Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. BioEssays 15: 105-111
7. Bouchet C, Spyratos F, Martin PM, Hacène K, Gentile A and Oglobine J (1994) Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 69: 398-405
8. Delannoy-Courdent A, Fauquette W, Dong-Le Bourhis X, Boilly B, Vandenbunder B and Desbiens X (1996) Expression of c-ets-1 and uPA genes is associated with fibroblast-induced tubulogenesis in normal mammary epithelial cells or with constitutive scattering in cancerous epithelial cells. Int J Dev Biol 40: 1097-1108
9. Delehedde M, Deudon E, Boilly B and Hondermarck H (1996) Heparan sulfate proteoglycans play a dual role in regulating fibroblast growth factor-2 mitogenic activtiy in human breast cancer cells. Exp Cell Res 229: 398-406
10. Deng G, Curriden SA, Wang S, Rosenberg S and Loskutoff D (1996) Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 134: 1563-1571
11. Desruisseau S, Ghazarossain-Ragni E, Chinot O and Martin PM (1996) Divergent effect of TGFβ on growth and proteolytic modulation of human prostatic cancer cell lines. Int J Cancer 66: 796-801
12. Ellis V, Behendt N and Danø K (1991) Plasminogen activation by receptor-bound urolinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem 266: 12752-12758
13. Fynan TM and Reiss M (1993) Resistance to inhibition of cell growth by transforming growth factor-β and its role in oncogenesis. Crit Rev Oncogen 4: 493-540
14. Geiser AG, Burmester JA, Webbink R, Roberts AB and Sporn MB (1992) Inhibition of growth by transforming growth factor-β following fusion of two nonresponsive human carcinoma cell lines. J Biol Chem 267: 2588-2593
15. Gould VE, Koukoulis GK and Virtanen I (1990) Extracellular matrix proteins and their receptors in the normal, hyperplastic and neoplastic breast. Cell Diff Dev 32: 409-416
16. Ivanovic V, Melman A, David-Joseph B, Valvic M and Geliebter J (1995) Elevated plasma levels of transforming growth factor beta 1 in patients with invasive prostate cancer. Nature Med 1: 282-284
17. Jankun J, Merrick HW and Goldblatt PJ (1993) Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. J Cell Biochem 53: 135-144
18. Jones JL, Critchley DR and Walker RA (1992) Alternation of stromal protein and integrin expression in breast: a marker of premalignant change? J Pathol 167: 399-406
19. Keski-Oja J, Blasi F, Leof EB and Moses HL (1988a) Regulation of synthesis and activity of urokinase plasminogen activator in A 549 human lung carcinoma cells by transforming growth factor-β. J Cell Biol 106: 451-459
20. Keski-Oja J, Raghow R, Sawdey M, Loskutoff DJ, Postlethwaite AE, Kang AH and Moses HL (1988b) Regulation of mRNAs for type-I plasminogen activator inhibitor, fibronectin, and type-I procollagen by transforming growth factor-β. J Biol Chem 263: 3111-3115
21. Laiho M, Saksela O and Keski-Oja J (1986) Transforming growth factor beta alters plasminogen activator activity in human skin fibroblasts. Exp Cell Res 164: 399-407
22. Lund LR, Rφmer J, Thomasset N, Solberg H, Pyke C, Bissell M, Danø K and Werb Z (1996) Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways. Development 122: 181-193
23. Markowitz SD and Roberts AB (1996) Tumour suppressor activity of the TGF-β pathway in human cancers. Cytokine Growth Factor 7: 93-102
24. Ossowski L, Russo-Payne H and Wilson E (1991) Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res 51: 274-281
25. Overall CM, Wrana JI and Sodek J (1991) Transcriptional and post-transcriptional regulation of 72-kDa gelatinase, type IV collagenase by transforming growth factor-β1 in human fibroblasts. J Biol Chem 266: 14064-14071
26. Prasad KN (1980) Butyric acid: a small fatty acid with diverse biological functions. Life Sci 17: 1351-1358
27. Reeder JA, Dickinson JI, Chevevix-Trench G and Antalis TM (1993) Sodium butyrate differentially modulates plasminogen activator inhibitor type-I, urokinase plasminogen activator, and its receptor in a human colon carcinoma cell. Teratogenesis, Carcinogenesis and Mutagenesis 13: 75-88
28. Reinartz J, Batrla R, Boukamp P, Fusenig N and Kramer MD (1993) Binding and activation of plasminogen at the surface of human keratinocytes. Exp Cell Res 208: 197-208
29. Stampfer MR, Yaswen P, Alhadeff M and Hosoda J (1993) TGFβ induction of extracellular matrix associated proteins in normal and transformed human mammary epithelial cells in culture is independent of growth effects. J Cell Physiol 155: 210-221
30. Valverius EM, Walker-Jones D, Bates SE, Stampfer MR, Clark R, McCormick F, Dickson RB and Lippman ME (1989) Production of and responsiveness to transforming growth factor-beta in normal and oncogene-transformed human mammary epithelial cells. Cancer Res 49: 6269-6274
31. Vassalli JD and Belin D (1987) Amiloride selectively inhibits the urokinase type plasminogen activator. FEBS Lett 214: 187-191
32. Waltz DA and Chapman HA (1994) Reversible adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem 269: 14746-14750
33. Yu H and Schultz R (1991) Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B 16 cells transfected with human urokinase sense and antisense genes. Cancer Res 50: 7623-7633
34. Zabrenetzky V, Hariss CC, Steeg PS and Roberts DD (1994) Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int J Cancer 59: 191-195